Novogene Statistics
Total Valuation
Novogene has a market cap or net worth of CNY 7.03 billion. The enterprise value is 5.37 billion.
Important Dates
The last earnings date was Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Jun 10, 2026 |
Share Statistics
Novogene has 405.06 million shares outstanding. The number of shares has decreased by -0.40% in one year.
| Current Share Class | 405.06M |
| Shares Outstanding | 405.06M |
| Shares Change (YoY) | -0.40% |
| Shares Change (QoQ) | +11.91% |
| Owned by Insiders (%) | 53.03% |
| Owned by Institutions (%) | 4.82% |
| Float | 136.73M |
Valuation Ratios
The trailing PE ratio is 46.84 and the forward PE ratio is 37.47.
| PE Ratio | 46.84 |
| Forward PE | 37.47 |
| PS Ratio | 3.06 |
| PB Ratio | 2.59 |
| P/TBV Ratio | 2.62 |
| P/FCF Ratio | 34.27 |
| P/OCF Ratio | 20.13 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 18.86, with an EV/FCF ratio of 26.15.
| EV / Earnings | 35.74 |
| EV / Sales | 2.33 |
| EV / EBITDA | 18.86 |
| EV / EBIT | 34.96 |
| EV / FCF | 26.15 |
Financial Position
The company has a current ratio of 2.60, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.60 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | 0.32 |
| Interest Coverage | 57.68 |
Financial Efficiency
Return on equity (ROE) is 5.78% and return on invested capital (ROIC) is 13.07%.
| Return on Equity (ROE) | 5.78% |
| Return on Assets (ROA) | 2.51% |
| Return on Invested Capital (ROIC) | 13.07% |
| Return on Capital Employed (ROCE) | 5.47% |
| Weighted Average Cost of Capital (WACC) | 8.41% |
| Revenue Per Employee | 1.03M |
| Profits Per Employee | 67,491 |
| Employee Count | 2,227 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 4.55 |
Taxes
In the past 12 months, Novogene has paid 18.72 million in taxes.
| Income Tax | 18.72M |
| Effective Tax Rate | 10.79% |
Stock Price Statistics
The stock price has increased by +16.82% in the last 52 weeks. The beta is 0.76, so Novogene's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +16.82% |
| 50-Day Moving Average | 17.56 |
| 200-Day Moving Average | 15.10 |
| Relative Strength Index (RSI) | 45.88 |
| Average Volume (20 Days) | 22,455,596 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novogene had revenue of CNY 2.30 billion and earned 150.17 million in profits. Earnings per share was 0.37.
| Revenue | 2.30B |
| Gross Profit | 989.82M |
| Operating Income | 153.51M |
| Pretax Income | 173.55M |
| Net Income | 150.17M |
| EBITDA | 263.97M |
| EBIT | 153.51M |
| Earnings Per Share (EPS) | 0.37 |
Full Income Statement Balance Sheet
The company has 1.76 billion in cash and 65.02 million in debt, with a net cash position of 1.69 billion or 4.18 per share.
| Cash & Cash Equivalents | 1.76B |
| Total Debt | 65.02M |
| Net Cash | 1.69B |
| Net Cash Per Share | 4.18 |
| Equity (Book Value) | 2.74B |
| Book Value Per Share | 6.69 |
| Working Capital | 1.79B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 349.25 million and capital expenditures -144.04 million, giving a free cash flow of 205.21 million.
| Operating Cash Flow | 349.25M |
| Capital Expenditures | -144.04M |
| Depreciation & Amortization | 110.45M |
| Net Borrowing | -17.02M |
| Free Cash Flow | 205.21M |
| FCF Per Share | 0.51 |
Full Cash Flow Statement Margins
Gross margin is 43.05%, with operating and profit margins of 6.68% and 6.53%.
| Gross Margin | 43.05% |
| Operating Margin | 6.68% |
| Pretax Margin | 7.55% |
| Profit Margin | 6.53% |
| EBITDA Margin | 11.48% |
| EBIT Margin | 6.68% |
| FCF Margin | 8.92% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 0.26%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 0.26% |
| Dividend Growth (YoY) | -10.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 12.14% |
| FCF Payout Ratio | 8.88% |
| Buyback Yield | 0.40% |
| Shareholder Yield | 0.65% |
| Earnings Yield | 2.14% |
| FCF Yield | 2.92% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Analyst Forecast
The average price target for Novogene is 19.53, which is 12.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 19.53 |
| Price Target Difference | 12.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 9.72% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novogene has an Altman Z-Score of 4.66 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.66 |
| Piotroski F-Score | 5 |